Alcohol use disorder (AUD) is a highly prevalent but severely under-treated disorder, with
only three widely-approved pharmacotherapies. Given that AUD is a very heterogeneous …

Alcohol addiction is a chronic relapsing brain disease characterized by an impaired ability to
stop or control alcohol use despite adverse consequences. A main challenge of addiction …

Identification of new medications for alcohol use disorder (AUD) is important for improving
treatment options. Baclofen, a GABAB agonist, has been identified as a potential …

Alcohol is one of the most widely used substances. Alcohol use accounts for 5.1% of the
global disease burden, contributes substantially to societal and economic costs, and leads …

Abstract introduction: The number of medications approved for AUD is small and they
generally have limited efficacy. We need new pharmacotherapies for the management of …

Alcohol use disorder (AUD) is a significant contributor to morbidity and mortality in the
United States. It contributes to over 140,000 annual deaths, to over 200 related diseases …

The GABAB receptors are metabotropic G protein-coupled receptors (GPCRs) that mediate
the actions of the primary inhibitory neurotransmitter, γ-aminobutyric acid (GABA). In the …

Aims The effects of alcohol on gamma-aminobutyric acid (GABA) transmission are key for
the development and maintenance of alcohol use disorder (AUD). Previous research …

Preclinical research over the past several decades has demonstrated a role for the γ-
aminobutyric acidB (GABAB) receptor in alcohol use disorder (AUD). This chapter offers an …

While most individuals with access to alcohol drink it recreationally, some vulnerable
individuals eventually lose control over their intake and progressively develop compulsive …